Squarepoint
ACAD icon

Squarepoint’s Acadia Pharmaceuticals ACAD Stock Holding History

Squarepoint’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,500
Closed -$274K – 4424
2025
Q1 		$274K Buy
+16,500
New +$300K ﹤0.01% 3802
2024
Q2 		– Sell
-20,200
Closed -$373K – 3984
2024
Q1 		$373K Buy
+20,200
New +$500K ﹤0.01% 3245

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Squarepoint's ACAD Position: Q2 2026 in Review

Squarepoint reduced its Acadia Pharmaceuticals (ACAD) stake by 62% in Q2 2026, selling an estimated $5.07M and leaving 140,013 shares worth $3.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

Squarepoint first reported a position in ACAD in Q4 2015 and has held it in 30 quarters since. The position peaked at $18.7M in Q1 2024. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Squarepoint held 140,013 shares of Acadia Pharmaceuticals worth $3.54M as of Q2 2026.
  • Squarepoint sold 230,445 Acadia Pharmaceuticals shares in Q2 2026, an estimated $5.07M.
  • Acadia Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #1876 holding.
  • Squarepoint first reported a position in Acadia Pharmaceuticals in Q4 2015 and has held it in 30 quarters since.
  • Squarepoint's Acadia Pharmaceuticals position peaked at $18.7M in Q1 2024.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.